The company has created V-10, a proprietary injectable drug that induces blood-vessel formation and reverses peripheral artery disease (PAD), a condition that leads to tissue damage and limb amputation/death. V-10 is minimally invasive, cost-efficient, and has secured IP and "freedom to operate." NangioTx's peptide-drug formulations provide localized treatment that promotes tissue regeneration and saves limbs in models of PAD.